Could Sars-Cov2 affect MS progression?

Arianna Di Stadio; Luigina Romani; Evanthia Bernitsas

doi:10.1016/j.msard.2020.102540

Could Sars-Cov2 affect MS progression?

Mult Scler Relat Disord. 2020 Nov:46:102540. doi: 10.1016/j.msard.2020.102540. Epub 2020 Sep 29.

Authors

Arianna Di Stadio¹, Luigina Romani², Evanthia Bernitsas³

Affiliations

¹ Otolaryngology Department, University of Perugia, Perugia, Italy; Neuroinflammation Lab, Queen Square UCL Neurology, London, UK. Electronic address: Arianna.distadio@unipg.it.
² Department of Experimental Medicine, University of Perugia, Perugia, Italy.
³ Multiple Sclerosis Center, Wayne State University, Detroit (MI), USA.

Abstract

A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection.

Keywords: COVID-19; Inflammasomes; Long-term sequela; Microglia; Sars-CoV2, Multiple sclerosis.

Publication types

Review

MeSH terms

COVID-19 / complications
COVID-19 / metabolism
COVID-19 / virology*
Disease Progression
Humans
Inflammasomes / metabolism*
Interleukin-1beta / metabolism
Interleukin-1beta / pharmacology
Multiple Sclerosis / complications*
Multiple Sclerosis / virology
SARS-CoV-2 / pathogenicity*

Substances

Inflammasomes
Interleukin-1beta